These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
96 related articles for article (PubMed ID: 16583786)
1. Effects of the ritonavir price increase on the cost of protease inhibitor regimens in United States. Lee WC; Williams KW; Chen E; Liu LZ; Pashos CL Manag Care Interface; 2006 Mar; 19(3):27-32. PubMed ID: 16583786 [TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results. Gatell J; Salmon-Ceron D; Lazzarin A; Van Wijngaerden E; Antunes F; Leen C; Horban A; Wirtz V; Odeshoo L; Van den Dungen M; Gruber C; Ledesma E; Clin Infect Dis; 2007 Jun; 44(11):1484-92. PubMed ID: 17479947 [TBL] [Abstract][Full Text] [Related]
7. Increased resilience to the development of drug resistance with modern boosted protease inhibitor-based highly active antiretroviral therapy. Lima VD; Gill VS; Yip B; Hogg RS; Montaner JS; Harrigan PR J Infect Dis; 2008 Jul; 198(1):51-8. PubMed ID: 18498238 [TBL] [Abstract][Full Text] [Related]